You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Regulatory impact statement (RIS) - update to the Required Advisory Statements for Medicine Labels (RASML)
The primary objective of government action in relation to mandatory advisory statements is to reduce the incidence of adverse events, and therefore reduce consequent consumer harm and public health costs, by ensuring that the non-prescription medicines supplied to the Australian community are labelled with information that will make the use of the medicines as safe and as effective as possible.
The secondary objective is to minimise administrative costs for industry thereby supporting the commercial viability of non-prescription medicines to Australian consumers.